Hostname: page-component-76d6cb85b7-f97m6 Total loading time: 0 Render date: 2026-07-11T04:41:00.078Z Has data issue: false hasContentIssue false

Beyond the Benefit of Doubt: Biases and Credibility in the Adjudication of Chronic Pain

Published online by Cambridge University Press:  17 April 2026

Rodrigo Deamo Assis
Affiliation:
Centre Intégré de Santé et Services Sociaux de l’Abitibi-Témiscamingue, Rouyn-Noranda, Québec, Canada
Steven P Cohen
Affiliation:
Anesthesiology, Neurology, Physical Medicine and Rehabilitation, Psychiatry, Neurological Surgery, Northwestern University Feinberg School of Medicine , Chicago, Illinois, USA
Hance Clarke
Affiliation:
Transitional Pain Service, Toronto General Hospital, University of Toronto , Toronto, Ontario, Canada
Nimish Mittal
Affiliation:
Temerty Faculty of Medicine, Division of Physical Medicine and Rehabilitation, University of Toronto , Toronto, Ontario, Canada
Mary-Ann Fitzcharles*
Affiliation:
Department of Rheumatology, McGill University , Montreal, Quebec, Canada
*
Corresponding author: Mary-Ann Fitzcharles; Email: mfitzcharles@sympatico.ca
Rights & Permissions [Opens in a new window]

Abstract

Patients living with nociplastic pain are at particular risk of being unfairly judged because their symptoms are subjective and occur without measurable abnormalities. Nociplastic pain, now recognized as a third category of pain alongside nociceptive and neuropathic pain, arises in the absence of tissue damage sufficient to explain the clinical presentation. This “unseen” pain affects at least ten percent of the population, commonly involves the musculoskeletal or visceral systems, and leads to substantial suffering and functional impairment. Validation of these chronic symptoms is often contentious because no objective biomarker or physical sign can reliably confirm their presence or severity. The concept of illness without measurable parameters challenges clinicians and conflicts with legal systems that rely heavily on objective evidence in adjudicating health-related questions. Most clinicians have limited training in medicolegal principles, standards of impartiality, or the ethical distinctions between patient advocacy and objective reporting. These challenges are amplified in cases involving chronic nociplastic pain, where the lack of observable findings complicates clinical interpretation and may conflict with traditional expectations for legal evidence. Bias, whether conscious or unconscious, may occur at multiple stages of the medicolegal process. Inaccurate, incomplete, or biased information from patients, treating clinicians, independent medical experts, insurers, or legal representatives can influence fairness, credibility, and decisional outcomes. This review summarizes key considerations in the adjudication of chronic nociplastic pain and examines how various sources of bias may shape medicolegal decision-making. Improving awareness of these risks and implementing strategies to reduce bias may promote a more reliable and equitable interface between clinical assessment and legal adjudication.

Information

Type
Independent Articles
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics
Figure 0

Figure 1. Overview of the principal factors of the person with chronic nociplastic pain.

Figure 1

Table 1. Core principles for an independent medical examination (IME)

Figure 2

Table 2. Key aspects of the medicolegal framework in selected countries worldwide

Figure 3

Table 3. Potential sources of bias

Figure 4

Table 4. Key points in the identification of bias against individuals with nociplastic pain, and steps to minimize them